Genentech Advances Lunsumio in Phase III Follicular Lymphoma
SOUTH SAN FRANCISCO, Calif. — September 16, 2026 Genentech announced that the Phase III CELESTIMO study of Lunsumio® (mosunetuzumab-axgb)...
Phase III
Advertisement
Cardiol Therapeutics Files US$150M Shelf Prospectus
Toronto, Ontario, Canada, September 10, 2026 Cardiol Therapeutics Inc. has filed a US$150 million preliminary short form base shelf...
Bayer Wins FDA Accelerated Approval for Sevabertinib
BERLIN — September 9, 2026 Bayer announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval...
Genentech Gains FDA Priority Review for Enspryng in MOGAD
SOUTH SAN FRANCISCO, Calif. — September 9, 2026 Genentech, a member of the Roche Group, announced that the U.S....
Roche Wins FDA Priority Review for Enspryng in MOGAD
BASEL, Switzerland — September 10, 2026 Roche announced that the U.S. Food and Drug Administration (FDA) granted Priority Review...
Advertisements
Novartis Reports Phase III HARBOR Setback for Del-desiran
BASEL — September 8, 2026 Novartis announced that its global Phase III HARBOR study of delpacibart etedesiran (del-desiran) in...
Mabwell Reports 9MW1911 COPD Phase Ib/IIa Results
Shanghai, China, September 4, 2026 Mabwell (Shanghai) Bioscience Co., Ltd. has announced Phase Ib/IIa clinical results for its investigational...
Lundbeck Advances Bexicaserin Research in Rare Epilepsy
Valby, Denmark, September 3, 2026 H. Lundbeck A/S will present new mechanistic and clinical research on bexicaserin (LP352) at...
Newron Completes Screening for Phase 3 Evenamide TRS Study
MILAN, Italy and MORRISTOWN, N.J., September 2, 2026 Newron Pharmaceuticals S.p.A. announced completion of screening for enrollment in its...
Can-Fite Reports Longer Overall Survival in Phase III Liver Cancer Study
RAMAT GAN, Israel, September 2, 2026 Can-Fite BioPharma Ltd. reported that blinded overall survival observed across the entire patient...
Advertisement
